News Release

Can an existing HIV medication slow the spread of COVID-19?

Team of Toronto researchers launches clinical trial to find out if existing HIV medication could prevent COVID-19 infection

Business Announcement

St. Michael's Hospital

Dr. Darrell Tan

image: "Early studies of the use of this medication as post-exposure prophylaxis therapy in other coronaviruses such as SARS and MERS have been promising," said Dr. Darrell Tan, the study's lead investigator who is also a scientist at the MAP Centre for Urban Health Solutions and an infectious disease physician at St. Michael's. "These are so-called 'cousin' viruses to COVID-19 and we want to understand whether lopinavir/ritonavir as PEP could impact its spread as well." view more 

Credit: MAP Centre for Urban Health Solutions, St. Michael's Hospital, Unity Health Toronto

A team of scientists from St. Michael's Hospital, Sinai Health and Sunnybrook Health Sciences Centre have launched a clinical trial to understand whether an existing drug used for HIV treatment and prevention may work to prevent COVID-19 infection.

The trial will examine whether post-exposure prophylaxis (PEP), which is a medication a person takes once they've been exposed to a virus to prevent infection, could halt or slow the spread of COVID-19 in groups of people who have been exposed to a confirmed case. The drug in question - Kaletra (lopinavir/ritonavir as PEP)- has long been used in this capacity to prevent HIV in those who have been exposed to the virus.

"Early studies of the use of this medication as post-exposure prophylaxis therapy in other coronaviruses such as SARS and MERS have been promising," says Dr. Darrell Tan, the study's lead investigator who is also a scientist at the MAP Centre for Urban Health Solutions and an infectious disease physician at St. Michael's. "These are so-called 'cousin' viruses to COVID-19 and we want to understand whether lopinavir/ritonavir as PEP could impact its spread as well."

Dr. Tan, along with his co-leads Dr. Allison McGeer, a senior clinician-scientist at the Lunenfeld-Tanenbaum Research Institute of Sinai Health, and Dr. Adrienne Chan, a clinician-investigator at the Sunnybrook Research Institute, will collaborate with Toronto Public Health to identify confirmed cases of COVID-19. They'll then connect with those exposed to confirmed cases to enroll them in the study.

"A great many people from all across Toronto have worked together to get this study started," says Dr. McGeer. "We know we need to be finding solutions that contribute to stopping the spread of this disease as quickly as possible."

The group of contacts of one patient with confirmed COVID-19 will be identified as a 'cluster.' Entire clusters will be randomized to receive either the medication or no intervention. The team of researchers will then track whether or not participants develop COVID-19 by asking them to complete self-tests for the virus weekly. To limit contact, the research team will rely on courier and virtual or phone meetings with participants.

This type of a study is called a ring trial design and was an effective method of using vaccines to eradicate smallpox and test treatments for Ebola.

"Kaletra is a drug that the HIV community has been using globally for two decades, and has also been commonly used at scale in low-resource settings. This means it could be easily scaleable not just in Canada, but internationally, if we are able to demonstrate its effectiveness in the prevention of COVID-19," says Dr. Chan, who is also an infectious diseases physician at Sunnybrook Health Sciences Centre.

Participants randomized to receive the study drug will take it for 14 days, as this is the current estimated incubation period for COVID-19.

"If this strategy works, it could be a major turning point in our global effort to stop a virus where, as we have seen, the outcomes can be devastating," says Dr. Tan. "We are hopeful that our work will bring us closer to understanding how to slow or contain the spread of COVID-19."

###

This research is funded by the Canadian Institutes of Health Research and the St. Michael's Hospital Foundation. For the purposes of this trial, the medication, Kaletra, has been donated in-kind by AbbVie, a biopharmaceutical company. The CIHR Centre for REACH in HIV/AIDS is also supporting this work.

About St. Michael's Hospital

St. Michael's Hospital provides compassionate care to all who enter its doors. The hospital also provides outstanding medical education to future health care professionals in more than 27 academic disciplines. Critical care and trauma, heart disease, neurosurgery, diabetes, cancer care, care of the homeless and global health are among the Hospital's recognized areas of expertise. Through the Keenan Research Centre and the Li Ka Shing International Healthcare Education Centre, which make up the Li Ka Shing Knowledge Institute, research and education at St. Michael's Hospital are recognized and make an impact around the world. Founded in 1892, the hospital is fully affiliated with the University of Toronto.

About Unity Health Toronto

Unity Health Toronto, comprised of Providence Healthcare, St. Joseph's Health Centre and St. Michael's Hospital, works to advance the health of everyone in our urban communities and beyond. Our health network serves patients, residents and clients across the full spectrum of care, spanning primary care, secondary community care, tertiary and quaternary care services to post-acute through rehabilitation, palliative care and long-term care, while investing in world-class research and education. For more information, visit http://www.unityhealth.to.

About Sunnybrook Health Sciences Centre

Sunnybrook Health Sciences Centre is inventing the future of health care for the 1.3 million patients the hospital cares for each year through the dedication of its more than 10,000 staff and volunteers. An internationally recognized leader in research and education and a full affiliation with the University of Toronto distinguishes Sunnybrook as one of Canada's premier academic health sciences centres. Sunnybrook specializes in caring for high-risk pregnancies, critically ill newborns and adults, offering specialized rehabilitation, and treating and preventing cancer, cardiovascular disease, neurological and psychiatric disorders, orthopaedic and arthritic conditions and traumatic injuries. The hospital also has a unique and national leading program for the care of Canada's war veterans.

About Sinai Health

Sinai Health Foundation takes the vision of Sinai Health's physicians, clinicians, scientists, and healthcare providers and helps turn it into a reality. Philanthropy is essential for advancing research, care, and outcomes for those facing cancer, a high-risk pregnancy, stroke recovery, and other conditions and diseases. It funds world-class facilities and offers patients access to some of the most impactful clinical trials and studies that have taken place over the past 30 years.

Media contacts:

To speak with Dr. Darrell Tan, please contact Ana Gajic at Ana.Gajic@unityhealth.to or 416-458-0629.

To speak with Dr. Allison McGeer, please contact Amanda Ferguson at amanda.ferguson@sinaihealth.ca or 647-248-7434.

To speak with Dr. Adrienne Chan, please contact Sybil Millar at sybil.millar@sunnybrook.ca or 416-480-4040.


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.